Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.53 |
| ▸ | CCR2 | P41597 | 6/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 2/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4914068 | 0.91 | PTGES (0.60) | PTGESCCR2KMOALDH1A1TSHR | |
| SCHEMBL4912640 | 0.83 | PTGES (0.53) | PTGESALDH1A1TSHRBCL2MDM2 | |
| SCHEMBL4922695 | 0.83 | PTGES (0.48) | PTGESALDH1A1TSHRBCL2MDM2 | |
| SCHEMBL4924661 | 0.82 | PTGES (0.67) | PTGESALDH1A1TSHRBCL2MDM2 | |
| SCHEMBL3574822 | 0.82 | PTGES (0.71) | PTGESALDH1A1TSHRBCL2MDM2 | |
| SCHEMBL4914078 | 0.81 | PTGES (0.61) | PTGESCCR2ALDH1A1TSHRABCB11 | |
| SCHEMBL4926174 | 0.81 | PLA2G10 (0.52) | PTGES | |
| SCHEMBL4923416 | 0.80 | PTGES (0.60) | PTGESCCR2ALDH1A1TSHRABCB11 | |
| SCHEMBL4224601 | 0.79 | PTGES (0.58) | PTGESCCR2ALDH1A1TSHRBCL2 | |
| SCHEMBL4918706 | 0.79 | PTGES (0.64) | PTGESALDH1A1TSHRBCL2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, ARG1 | PTGES 35/4885CCR2 242/4885KMO 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.